Results for tag: "Tralokinumab"

Tralokinumab is a human monoclonal antibody used to treat severe asthma and chronic obstructive pulmonary disease (COPD). It is a type of biologic drug, which works by blocking the action of a protein called interleukin-13 (IL-13). This protein is involved in the inflammation that causes asthma and COPD. Tralokinumab is administered as an injection and is approved for use in adults and adolescents aged 12 and over. Tralokinumab is a relatively new drug, and is part of a growing class of biologic drugs used to treat respiratory diseases. It is seen as a potential alternative to traditional treatments such as corticosteroids, which can have serious side effects. Tralokinumab is also being studied for its potential to treat other respiratory diseases, such as idiopathic pulmonary fibrosis. Some companies in the Tralokinumab market include AstraZeneca, GlaxoSmithKline, and Novartis. Show Less Read more